Abstract: Nanoparticles showgreat potential for drug delivery. However,suitable nanostructures capable of loading arange of drugs together with the co-delivery of siRNAs,which avoid the problem of cation-associated cytotoxicity,are lacking. Herein, we report an small interfering RNA( siRNA)-based vesicle (siRNAsome), which consists of ah ydrophilic siRNAs hell, at hermal-and intracellular-reduction-sensitive hydrophobic median layer,a nd an empty aqueous interior that meets this need. The siRNAsome can serve as aversatile nanostructure to load drug agents with divergent chemical properties,therapeutic proteins as well as co-delivering immobilized siRNAs without transfection agents.Importantly,the inherent thermal/ reduction-responsiveness enables controlled drug loading and release.W hen siRNAsomes are loaded with the hydrophilic drug doxorubicin hydrochloride and anti-P-glycoprotein siRNA, synergistic therapeutic activity is achieved in multidrug resistant cancer cells and atumor model.
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The use of small interfering RNA( siRNA) to suppress the activity of specific genes is an ovel therapeutic option for disease therapy.
[1] However,lack of safe and efficient delivery carriers impedes the development of RNAi nterference (RNAi)t herapeutics for potential clinical use. [2] Them ost commonly used siRNAd elivery systems are cationic and include polymers, [3] lipids, [4] and inorganic materials. [5] These cationic materials compress siRNAs into nanoformulated polyplexes through electrostatic interaction to enable siRNAs to enter cells and, crucially,a void nuclease digestion. However,s trongly cationic carriers normally induce severe cytotoxicity in normal tissue by destabilizing cell membranes. [6] They can also interact with the anionic proteins in the plasma, resulting in unstable siRNApolyplexes and rapid clearance. [7] As such, an ew strategy for the development of cation-free siRNAd elivery systems is greatly needed. Recently,v arious nucleic acid nanostructures (NANs), such as spherical nucleic acids (SNAs), [8] DNAnanoparticles, [9] and nucleic acid nanogels [10] have been developed for siRNA delivery,o bviating the need for cationic components.T hese cation-free NANs are incapable of triggering positive-chargeinduced cytotoxicity and plasma protein interaction, and thus represent ap romising new direction for the construction of carriers for siRNAd elivery.
Given the complicated pathological mechanism/s of refractory disease,c o-delivery of siRNAi nc onjunction with other drug types may offer complimentary and more potent efficacy, relative to conventional monotherapeutic strategies. [11] However,most siRNAand drug co-delivery systems still utilize ac ationic component to encapsulate siRNAa nd are hence subject to the same cytotoxicity potential. Recently, drug-cored [12] or drug-loaded [13] micellar SNAs,inwhich drugs are anchored or encapsulated inside apolymer core together with anucleic-acid-immobilizing shell, represent apromising approach for siRNAa nd drug co-delivery without cationic materials.D espite these improvements,t hese micellar SNAs nanostructures still have ak ey limitation;t he hydrophobic micellar core only allows loading of hydrophobic small molecules, [14] excluding amyriad of hydrophilic molecules and proteins.C onsequently,d eveloping ac ation-free versatile nanostructure,also capable of loading hydrophilic small drugs and biomolecular payloads,ishighly desirable.
Here,weconstructed anovel drug delivery nanostructure, an siRNA-based vesicle (siRNAsome), originating from the self-assembly of siRNA-disulfide-poly(N-isopropylacrylamide) (siRNA-SS-PNIPAM) diblock copolymers (Scheme 1). Ther esultant siRNAsome consists of ah ydrophilic siRNAs tabilization shell, at emperature-and intracellular-reduction-sensitive hydrophobic median layer, and an empty aqueous interior.This design enables hydrophilic small molecules and biomolecules to be encapsulated within the vesicular interior as the polymersome is fabricated, [15] but critically,a lso enables hydrophobic small molecules or drugs to be incorporated into at emperature-responsive hydrophobic layer. Thus,the siRNAsome technology can co-deliver immobilized siRNAs plus loaded small-molecule drugs or proteins into cells without using cationic agents.T oo ur knowledge,t his is the first report of an siRNAsome and its promising potential in drug co-delivery.
siRNA-SS-PNIPAM was readily prepared by an exchange reaction between PNIPAM orthopyridyl disulfide (PNIPAM-SS-Py) and mercapto siRNA( siRNA-SH). The synthetic approach is illustrated in Figure S1 in the Supporting Information. Firstly,P NIPAM (characterization data is presented in Table S1 in the Supporting Information) terminated with ac arboxyl group was reacted with 2-(2-pyridyldithio)ethylamine to yield PNIPAM-SS-Py.The 1 HNMR data showed that the conversion ratio of carboxyl groups to -SS-Py groups was 90 %( Supporting Information, Figure S2 ). After 24 h, the resulting polymer from the exchange reaction between PNIPAM-SS-Py and siRNA-SH, was purified by dialysis,c entrifugation, and washed with isopropanol to remove byproducts,u nreacted siRNAa nd PNIPAM. Ultra performance liquid chromatography (UPLC) results show that the resulting siRNA-SS-PNIPAM copolymer was narrowly dispersed with as ingle peak, free from unreacted siRNAa nd PNIPAM (Supporting Information, Figure S3 ), thereby indicating the successful synthesis and purification of siRNA-SS-PNIPAM.
As PNIPAM is temperature-responsive, [16] siRNA-SS-PNIPAM copolymers can self-assemble into nanoparticles upon heating, with al ower critical solution temperature (LCST) of 30 8 8C, 31 8 8C, and 32 8 8Cfor PNIPAM components of 7kDa, 13 kDa, and 19 kDa, respectively (Supporting Information, Table S2 ). This enables nanoparticles to control drug loading during the self-assembly process.G el retardation assays show that after siRNA-SS-PNIPAM heating, no free siRNAw as released and all siRNAs tayed in the initial position (Figure 1a) , further confirming successful nanoparticle formulation. Dynamic light scattering (DLS) measurements show that the formulated nanoparticles ranged in particle size from 126 nm to 135 nm (Figure 1b and Supporting Information, Table S2 ) while exhibiting very narrow polydispersity index (PDI). Tr ansmission electron microscopy (TEM) images further confirmed the particle size.M ore importantly,aclear vesicular morphology,w ith an empty interior and as olid layer, was observed in nanoparticles derived from PNIPAMs of three different molecular weights (Figure 1cand Supporting Information, Figure S4 ), indicating the successful formation of siRNAsome.F urthermore,t he siRNAsomes are very stable under physiological condition, their particle size was constant and no siRNAr elease was observed even after up to 7days of storage (Supporting Information, Figure S5 ). Thes iRNAsomes derived from PNIPAMs of 19 kDa in molecular weight showed the best dilution stability (lowest critical aggregation concentration, CAC; Supporting Information, Table S2 ). Using PNIPAM of this molecular weight, the drug-loading utility of siRNAsome was confirmed by performing an encapsulation experiment using the hydrophilic drug doxorubicin hydrochloride (Dox·HCl), the hydrophobic drug docetaxel (DTX), and the hydrophilic protein bovine serum albumin (BSA). As shown in Tables S3 in the Supporting Information, successful encapsulation of Dox·HCl, DTX, and BSA was achieved during the siRNAsome fabrication process.U sing siRNA-SS-PNIPAM copolymer, upon heating, loading efficacies of approximately 37 %, 43 %, and 33 %( for Dox·HCl, DTX, and BSA, respectively) were achieved at at heoretical drug loading content of 20 wt.%. These data confirm that the siRNAsome nanostructure can serve as au niquely versatile carrier for therapeutic agents with diverse chemical properties and types.
To ensure siRNAsomes could lead to intracellular-environment-triggered drug release in cells,aredox-sensitive disulfide bond, [17] covalently linking the siRNAand PNIPAM, was incorporated into the siRNAsome.T oc onfirm whether intracellular redox conditions can rupture this bond, leading to cargo release,siRNAsome nanoparticles were treated with 10 mm dithiothreitol (DTT) solution at 37 8 8Cf or different durations (0-24 h) and assessed by gel electrophoresis and DLS/TEM measurements.Asshown in Figure 2a ,gel electrophoresis clearly showed siRNAr elease,s upporting our hypothesis that the introduced disulfide bond was vulnerable to reducing cellular environments,t riggering the cleavage of siRNA-SS-PNIPAM. DLS measurements showed that siRNAsomes maintained essentially the same particle size (126 nm) after 24 hi nt he absence of DTT,i ndicating excellent colloidal stability of the siRNAs hell-stabilized nanoparticles.H owever,t he siRNAsomes rapidly expanded to approximately 235 nm and 341 nm in size following 6hand 24 hi ncubation with 10 mm DTT (Figure 2b) , respectively, indicating that reduction results in siRNAsome swelling. Cleavage of the disulfide bond and destruction of the vesicle structure is illustrated in Figure 2c and further confirmed by TEM. As shown in Figure 2d ,t he vesicle structure was disrupted after 12 hincubation with 10 mm DTT.The interior of the siRNAsomes became black due to the staining of released siRNA, while the unreduced siRNAsomes possessed ac lear-colored interior (Figure 2d ). This suggests that reduction triggers disulfide cleavage and siRNAr elease. Thek inetics of drug release were then monitored. As shown in Figure 2e ,t he siRNAsomes released Dox·HCl rapidly in the presence of 10 mm DTT.After 24 htreatment with DTT, more than 75 %o ft he encapsulated drugs were released. In contrast, less drug release,2 3%,w as observed after 24 h without DTT treatment. Drug release was gradual, with ac onstant release rate,i ndicating the potential for ab etter drug exposure profile.
To confirm the ability of siRNAsomes to deliver siRNAs into cells,w ithout the assistance of any cationic agents, multidrug resistant (MDR) MCF-7 cells were incubated with FAM-labeled siRNAsomes.A ss hown in Figure 3a ,s iRNAsomes were efficiently taken up by cells,c ompared to free siRNA. Thee nhanced cellular uptake of siRNAsomes was further confirmed by confocal laser scanning microscopy (CLSM) imaging (Figure 3b ). Thee fficient cellular uptake ability of the siRNAsomes could be mediated by endocytosis after binding to class Ascavenger receptors. [8a,18] Interestingly, the high uptake of siRNAsomes in MDR MCF-7 cells did not cause any measurable toxicity,e ven at ah igh siRNA concentration of 1200 nm (Figure 3c ), indicating the excellent biocompatibility of the cation-free siRNAsome.P revious studies have highlighted the role played by the P-glycoprotein (Pgp) in the development of drug resistance, [19] as Pgp effectively pumps out administered drugs.T od etermine whether the siRNAsomes could effectively deliver Pgpgene-silencing siRNAs into MDR MCF-7 cells,M CF-7 MDR cells were incubated with siRNAsomes incorporating Pgp-siRNAf or 2days and then Pgp mRNAe xpression was detected using real-time (RT) PCR. After sequence-specific Pgp gene silencing by the siRNAsome,t he Pgp mRNA expression level was reduced by approximately 42 %, at an siRNAc oncentration of 200 nm (Figure 3d ). This study indicates the cation-free siRNAsomes can deliver attached Pgp-siRNAt ot arget the Pgp drug exporter, and shows its potential to overcome drug resistance of MDR cells.T hus, siRNAsomes attached to Pgp-siRNA, combined with anticancer drugs,m ay offer enhanced MDR cell killing by inducing synergistic therapeutic effects.
Pgp-siRNAa nd Dox·HCl were co-delivered to test the synergistic potential of the siRNAsomes against MDR cancer cells (Figure 4a ). Flow cytometry,c onfocal imaging,a nd the MTT assay were used to evaluate cytotoxicitya nd efficacy. Cytotoxicity assessments demonstrated that Pgp mRNA knockdown significantly improved the activity of Dox·HCl, whereas scrambled (control) siRNAs and free Dox·HCl had much lower effect (Figure 4b) . Furthermore,i nn on-MDR i.e., MCF-7, cells,w hich do not actively pump out Dox·HCl, the siRNAsomes (Dox·HCl loaded) attached with scrambled siRNAs or Pgp-siRNAs had similar cytotoxicity,w hich was lower than that of Dox·HCl under the same conditions (Supporting Information, Figure S6a ). These results suggest the synergistic effect of Pgp-siRNAa nd Dox·HCl against MDR cells.Incontrast, Dox·HCl administration without Pgp mRNAk nockdown or siRNAsome-based delivery,r esulted in less cytotoxicitya st he MDR cells could efflux Dox·HCl. These data were corroborated by the increased fluorescence intensity of Dox·HCl in cells receiving co-delivered PgpsiRNAc ompared to cells treated with free drug or nanoparticles delivering Dox·HCl with scrambled siRNA ( Figure 4c) . These data are further confirmed by CLSM that shows more Dox·HCl (red fluorescence) present inside MDR MCF-7 cells when treated with siRNAsomes attached to PgpsiRNA(Supporting Information, Figure S7 ). It should also be noted that treatment of non-MDR MCF-7 cells with siRNAsomes (Dox·HCl loaded) attached to scrambled siRNAs or Pgp-siRNAs resulted in similar Dox·HCl fluorescence intensities.T his level of fluorescence intensity was reduced in comparison to non-MDR MCF-7 cells treated with free Dox·HCl under the same conditions (Supporting Information, Figure S6 b,c) . Furthermore,t he in vivo delivery ability of the siRNAsome was evaluated. As shown in Figure S8 in the Supporting Information, more Dox·HCl accumulated in the tumor when using siRNAsome-based delivery in comparison with treatment with free Dox·HCl. Subsequently,t he tumor growth inhibition ability of the siRNAsome was tested in an MDR MCF-7 subcutaneous tumor model by codelivering Dox·HCl and Pgp-siRNA. Impressively,t he Dox·HCl-loaded siRNAsomes attached to Pgp-siRNAd isplayed the strongest tumor growth inhibition ability (Figure 4d) , which is in line with the in vitro performance,w ith negligible body weight changes (Figure 4e) . Collectively, these results show that the siRNAsome can co-deliver Dox·HCl and Pgp-siRNAt oa chieve synergistic therapeutic efficacya gainst MDR cancer cells and atumor model. In summary,w eh ave fabricated au nique siRNA-based vesicle,termed the siRNAsome.T his can serve as aversatile nanostructure to deliver payloads of small-molecule drugs and biomolecular agents that have divergent chemical properties.I mportantly,b ye xploiting the temperature-and intracellular-reduction-responsiveness,d rug loading into the siRNAsome and drug release in cells can be controlled. Moreover,incorporation of asiRNAshell not only stabilizes the nanoparticle,b ut provides the opportunity to deliver drug-action-complementary siRNAs,t hus realizing siRNA co-delivery with other drug types.T he utility of this design was demonstrated by showing that the siRNAsomes attached to Pgp-siRNAand loaded with Dox·HCl displayed improved synergistic efficacy against MDR MCF-7 cancer both in vitro and in vivo.W eexpect that our cation-free siRNAsome could serve as av ersatile nanostructure for drug, therapeutic protein, and siRNAc o-delivery to target ab road range of diseases. 
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